SML3725
Icotinib
≥98% (HPLC), EGFR tyrosine kinase inhibitor , powder
别名:
(3-Ethynyl-phenyl)(7,8,10,11,13,14-hexahydro-6,9,12,15-tetraoxa-1,3-diazacyclododeca[b]naphthalen-4-yl)-amine, 4-[(3-Ethynylphenyl)amino]-6,7-benzo-12-crown-4-quinazoline, BPI 2009, BPI 2009H free base, BPI-2009, BPI-2009H free base, BPI2009, BPI2009H free base, Conmana
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C22H21N3O4
化学文摘社编号:
分子量:
391.42
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
产品名称
Icotinib, ≥98% (HPLC)
SMILES string
N(c4cc(ccc4)C#C)c1ncnc2c1cc3c(c2)OCCOCCOCCO3
InChI key
QQLKULDARVNMAL-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
storage condition
protect from light
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
Icotinib is an orally active, potent and highly selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (IC50 = 5 nM) that inhibits EGFR-mediated intracellular tyrosine phosphorylation (IC50 = 45 nM; A431 cells) and cancer proliferation in cultures (A431/BGC-823 IC50 = 1.0/4.1 μM) and in vivo (30-120 mg/kg via daily p.o. to mice with A431, A549, H460 and HCT8 xenografts).
Orally active, potent and highly selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with anti-cancer efficacy in vitro and in vivo.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies
Lung Cancer, 76(2), 177-182 (2012)
Icotinib, a potent and specific EGFR tyrosine kinase inhibitor, inhibits growth of squamous cell carcinoma cell line A431 through negatively regulating AKT signaling
Biomedicine and Pharmacotherapy, 67(5), 351-356 (2013)
Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer
Oncology Reports, 27(6), 2066-2072 (2012)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持